SequelSEC

Fulcrum Therapeutics, Inc. FULC

Pharmaceutical Preparations · CIK 0001680581 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$22.69M
Fiscal year ended 2025-12-31
Free cash flow
-$16.96M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$296.08MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$4.45Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio27.40x98th

Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 and net income of -$20.33M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Fulcrum Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Fulcrum Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Revenue$0$0$0$0$0$80.00M$0$871.00K$759.00KUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$22.69M-$21.86M-$19.82M-$19.43M-$25.13M$52.49M-$29.83M-$27.99M-$27.44MUnavailable
Net income-$20.33M-$19.60M-$17.30M-$16.57M-$21.70M$55.41M-$26.87M-$24.76M-$24.02MUnavailable
Research & development$15.42M$14.30M$12.99M$11.71M$14.64M$17.26M$19.77M$19.00M$18.24MUnavailable
Weighted-average diluted sharesUnavailableshares 62.60Mshares 62.54MUnavailableshares 62.41Mshares 63.59Mshares 61.98MUnavailableshares 61.82MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPSUnavailable$-0.31$-0.28Unavailable$-0.35$0.87$-0.43Unavailable$-0.39Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.28M$7.56M$6.83M$7.72M$8.42M$10.25M$10.06M$9.86M$9.96MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Fulcrum Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Cash & equivalents$197.53M$47.08M$42.59M$58.21M$72.63M$86.70M$39.95M$25.56M$30.08MUnavailable
Total assets$366.28M$214.86M$228.84M$260.72M$279.01M$294.26M$232.59M$257.69M$278.88MUnavailable
Current assets$357.48M$205.86M$219.37M$249.92M$267.49M$280.29M$217.95M$242.20M$262.49MUnavailable
Total liabilities$17.28M$16.49M$14.46M$17.68M$21.72M$20.47M$19.00M$22.50M$23.42MUnavailable
Current liabilities$13.05M$11.63M$8.98M$11.04M$14.51M$12.70M$10.69M$13.68M$14.08MUnavailable
Total equity incl. NCI$349.00M$198.37M$214.38M$243.03M$257.29M$273.79M$213.59M$235.19M$255.46MUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.59M$2.86M$1.75M$1.16M$4.04M$3.58M$3.86M$2.76M$3.57MUnavailable

Cash flow

Fulcrum Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Operating cash flow-$16.80M-$14.19MUnavailable-$16.76M-$19.07M$58.90M-$25.28M-$23.16M-$22.91MUnavailable
Capital expenditures$159.00K$90.00KUnavailable$231.00K$19.00K$0$28.00K$77.00K$65.00KUnavailable
Investing cash flow-$1.05M$18.61MUnavailable$2.26M$4.35M-$12.51M$38.13M$18.35M$19.02MUnavailable
Financing cash flow$168.30M$64.00KUnavailable$83.00K$635.00K$377.00K$1.65M$287.00K$0Unavailable
Net change in cash$150.46M$4.49MUnavailable-$14.42M-$14.09M$46.77M$14.50M-$4.52M-$3.89MUnavailable
Stock-based compensation$3.07M$3.36M$2.88M$2.48M$3.82M$4.34M$3.92M$3.45M$3.74MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Fulcrum Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312025-09-302025-06-302024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Free cash flow-$16.96M-$14.28MUnavailable-$16.99M-$19.09M$58.90M-$25.31M-$23.24M-$22.97MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable65.6%Unavailable-3213.8%-3615.3%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable73.6%Unavailable-2667.6%-3026.5%Unavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable5.4%Unavailable396.0%492.4%Unavailable
Current ratio27.40x17.70x24.42x22.63x18.44x22.07x20.38x17.71x18.65xUnavailable
Revenue YoY growthUnavailableUnavailable-100.0%-100.0%-100.0%Unavailable-100.0%27.2%-35.8%Unavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-2842.3%-3164.3%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable21.6%Unavailable2181.3%2402.9%Unavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable0.0%Unavailable8.8%8.6%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FULC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-27View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.